Drug intelligence / Profile preview

sulfacetamide + prednisolone

Development stage
Approved
Lead developer
Bausch + Lomb
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Sulfacetamide + prednisolone is a combination ophthalmic medication containing two active ingredients: sulfacetamide, a sulfa antibiotic, and prednisolone, a corticosteroid. Sulfacetamide inhibits bacterial growth by interfering with folic acid synthesis in susceptible bacteria, providing bacteriostatic action against organisms such as Escherichia coli, Staphylococcus aureus, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Prednisolone acts as an anti-inflammatory agent by suppressing the immune response to reduce swelling, redness, itching, and pain in the eye. This combination is primarily used to treat inflammatory ocular conditions where there is either an existing bacterial infection or risk of one—such as conjunctivitis or chronic anterior uveitis—and for preventing damage from chemicals or foreign objects in the eye. The product is available as an ophthalmic solution or ointment for topical use only[1][2][3][4][5][7].

Brand names
BlephamideIsopto CetapredMetimydPredamidePredsulfairSulphrinSulsterVasocidinOptimydBlephamide S.O.P.CetapredOcu-Lone C
Other names
sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution
02

Targets

DHPS (Dihydropteroate synthase)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on sulfacetamide + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfacetamide + prednisolone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call